44 23

Full metadata record

DC FieldValueLanguage
dc.contributor.author김근호-
dc.date.accessioned2019-11-30T18:36:52Z-
dc.date.available2019-11-30T18:36:52Z-
dc.date.issued2017-09-
dc.identifier.citationKIDNEY RESEARCH AND CLINICAL PRACTICE, v. 36, no. 3, page. 209-223en_US
dc.identifier.issn2211-9132-
dc.identifier.issn2211-9140-
dc.identifier.urihttp://www.krcp-ksn.org/journal/view.html?doi=10.23876/j.krcp.2017.36.3.209-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/115659-
dc.description.abstractAnemia, complicating the course of chronic kidney disease, is a significant parameter, whether interpreted as subjective impairment or an objective prognostic marker. Renal anemia is predominantly due to relative erythropoietin (EPO) deficiency. EPO inhibits apoptosis of erythrocyte precursors. Studies using EPO substitution have shown that increasing hemoglobin (Hb) levels up to 10-11 g/dL is associated with clinical improvement. However, it has not been unequivocally proven that further intensification of erythropoiesis stimulating agent (ESA) therapy actually leads to a comprehensive benefit for the patient, especially as ESAs are potentially associated with increased cerebro-cardiovascular events. Recently, new developments offer interesting options not only via stimulating erythropoeisis but also by employing additional mechanisms. The inhibition of activin, a member of the transforming growth factor superfamily, has the potential to correct anemia by stimulating liberation of mature erythrocyte forms and also to mitigate disturbed mineral and bone metabolism as well. Hypoxia-inducible factor prolyl hydroxylase inhibitors also show pleiotropic effects, which are at the focus of present research and have the potential of reducing mortality. However, conventional ESAs offer an extensive body of safety evidence, against which the newer substances should be measured. Carbamylated EPO is devoid of Hb augmenting effects whilst exerting promising tissue protective properties. Additionally, the role of hepcidin antagonists is discussed. An innovative new hemodialysis blood tube system, reducing blood contact with air, conveys a totally different and innocuous option to improve renal anemia by reducing mechanical hemolysis.en_US
dc.language.isoen_USen_US
dc.publisherKOREAN SOC NEPHROLOGYen_US
dc.subjectActivinen_US
dc.subjectAnemiaen_US
dc.subjectErythropoiesis stimulating agenten_US
dc.subjectHepcidinen_US
dc.subjectHypoxia inducible transcription factoren_US
dc.titleTreatment of renal anemia: Erythropoiesis stimulating agents and beyonden_US
dc.typeArticleen_US
dc.relation.no3-
dc.relation.volume36-
dc.identifier.doi10.23876/j.krcp.2017.36.3.209-
dc.relation.page209-223-
dc.relation.journalKidney Research and Clinical Practice-
dc.contributor.googleauthorBiggar, Patrick-
dc.contributor.googleauthorKim, Gheun-Ho-
dc.relation.code2017034475-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidkimgh-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE